FDA expands Sprycel approval to include certain children with acute lymphoblastic leukemia

The FDA expanded the approval of dasatinib tablets to include its use with chemotherapy for children aged 1 year or older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Read more: https://www.healio.com/hematology-oncology/leukemia/news/online/%7Bd076ee13-cf60-4cb3-9968-78d2cbf0a76f%7D/fda-expands-sprycel-approval-to-include-certain-children-with-acute-lymphoblastic-leukemia